We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Supercomputing Technology Creates Opportunities for Drug Discovery

By LabMedica International staff writers
Posted on 25 Jan 2011
A faster and cost-effective technique to scan molecular databases could put scientists on the fast track to developing new drug treatments.

A team led by Dr. More...
Jerome Baudry of the University of Tennessee and the US Department of Energy's Oak Ridge National Laboratory (ORNL) Center for Molecular Biophysics (Oak Ridge, USA) adapted a widely used existing software to allow supercomputers such as ORNL's Jaguar to filter through massive molecular databases and pinpoint chemical compounds as potential drug candidates.

The research was published online December 2010 online ahead of print in the Journal of Computational Chemistry. "Our research is the missing link between supercomputers and the huge data available in molecular databases like the Human Genome Project,” Dr. Baudry said. "We have an avalanche of data available to us, and now we need to translate that data into knowledge.”

Such translation is vital for the first stages of drug development, in which researchers look for applicable chemicals that interact with a target in the body, typically a protein. If the chemical is suitable, it attaches onto the protein and produces a desirable effect in the cell. However, with thousands of known proteins and millions of chemicals as potential drugs, the number of possible combinations is enormous. "It is very expensive and time-consuming to measure these interactions experimentally,” Dr. Baudry stated. "But with supercomputers, we can process millions of molecules a day.”

The fast and efficient processing of molecules gives scientists an opportunity to take risks on previously unexamined drug candidates, which could lead to diverse and novel classes of drugs. "Before, we threw away a lot of information because molecules did not have a preferred profile,” Dr. Baudry noted. "Now, every molecule can be examined without worrying about wasting resources.”

The scientists have already begun work to launch the research into reality through a new collaboration supported by the US National Institutes of Health (Bethesda, MD, USA). The project team plans to put the computational development to work on ORNL supercomputers to search for chemicals that could treat prostate cancer.

"Our development work is the computational equivalent of building the Saturn V rocket,” Dr. Baudry concluded. "Now we want to fly it to the moon.”

Related Links:

Oak Ridge National Laboratory Center for Molecular Biophysics




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.